Sintilimab plus a bevacizumab biosimilar (IBI305) versus sor...

🤖 Plain-English Summary

This research explores Sintilimab plus a bevacizumab biosimilar (IBI305) versus sor..., contributing new insights to the field of Medicine & Biology.

🔑 Key Findings

Research demonstrates significant advances in patient outcome data
Study provides new evidence regarding clinical efficacy results
Findings open new directions for biological mechanism insights

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📜 Copyright Notice: This page shows only metadata (title, authors, journal, date) and an original AI-generated summary. No abstract or full article text is copied. The original research is the intellectual property of its authors and publisher. ScienceTrace does not reproduce copyrighted content.

← More Medicine & Biology All Research Articles

📋 Article Details

Category	🧬 Medicine & Biology
Published	Jun 15, 2021
Journal	The Lancet Oncology
Authors	Zhenggang Ren, Jianming Xu, Yuxian Bai, Aibing Xu, Shundong Cang
DOI	10.1016/s1470-2045(21)00252-7
Citations	1,107
Source	OpenAlex

🗂️ Research Categories

🤖 Artificial Intelligence 🧬 Medicine & Biology ⚛️ Physics & Space Science ⚙️ Engineering & Technology ∑ Mathematics

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

🤖 Plain-English Summary

🔑 Key Findings

💡 Why This Matters

📋 Article Details

🗂️ Research Categories

🔗 Related Resources

More 🧬 Medicine & Biology Research